Stock Drop for Novavax on Thursday
In the ever-evolving landscape of the coronavirus vaccine market, Novavax's Nuvaxovid vaccine has struggled to match the commercial success of the dominant mRNA vaccines from Pfizer-BioNTech and Moderna. As demand for Nuvaxovid wanes in the post-pandemic era, the company is pivoting its strategy, focusing on partnerships to sustain revenues and broaden its pipeline beyond COVID-19.
The most significant of these partnerships is with Sanofi, which will take over Nuvaxovid's commercialization in the U.S. and Europe starting from late 2025. This move frees Novavax from operational costs and provides upfront payments, as well as future royalties. The partnership is not limited to COVID-19 vaccines; it also explores combination vaccines with influenza, leveraging Novavax’s proprietary Matrix-M adjuvant technology. Sanofi's global vaccine commercialization strength is expected to boost Nuvaxovid's market presence, particularly amid regulatory changes and variable demand.
Novavax's agility is evident in its regulatory strategy. In May 2025, the FDA approved an updated Nuvaxovid formulation targeting newer variants and approved for use in people aged 12 and older in the EU, maintaining relevance in a competitive field dominated by mRNA vaccines.
Meanwhile, Pfizer and Moderna continue to lead with their mRNA platform vaccines. However, Moderna faced setbacks, such as the termination of a contract for a bird flu mRNA vaccine, while Novavax is advancing an experimental bird flu vaccine with expected BARDA support.
Recently, Novavax submitted a request to expand the conditional marketing authorization for its Nuvaxovid vaccine in the European Union (EU) to include people aged 12 to 17. However, this submission did not prevent investors from trading its stock down on Thursday, reflecting the vaccine's status as a relative latecomer in established markets.
It is worth noting that the authorization for Nuvaxovid in Canada does not significantly impact its stock trading or affect the pediatric population vaccination rates. The news item about Novavax's submission is arguably the more important one in the paragraph, signalling the company's continued efforts to stay relevant in the competitive vaccine market.
As of mid-2025, Nuvaxovid sales are tapering off, with the company projecting 2025 revenue of about $975 million to $1.025 billion, down from pandemic-era highs but steady compared to the decline in demand for the vaccine. The authorization for Nuvaxovid in Canada occurred in February, and deliveries to Canada commenced on Tuesday, March 29.
Despite these developments, Novavax's CEO, Stanley Erck, remains optimistic, stating that the company is continuing to see spikes in COVID-19 across Europe and recognizes the need to improve vaccination rates, particularly in the pediatric population. The authorization for Nuvaxovid in Canada does not change the need for diversified vaccine options, as stated by Erck.
In summary, Novavax's Nuvaxovid currently holds a smaller share of the coronavirus vaccine market compared to the dominant mRNA vaccines by Pfizer-BioNTech and Moderna. The company is pivoting from direct commercialization to partnerships, notably with Sanofi, to sustain revenues through royalties and to broaden its pipeline beyond COVID-19 into other infectious and non-infectious diseases. This strategic shift reflects Novavax's adaptation to reduced COVID-19 vaccine demand and intense market competition from mRNA-based products.
- In an attempt to broaden its income sources and maintain relevance in the competitive vaccine market, Novavax is focusing on financial partnerships, such as the one with Sanofi, to sustain revenues and diversify its pipeline beyond COVID-19.
- The strategic partnership with Sanofi goes beyond the realm of COVID-19 vaccines, exploring combination vaccines with influenza, employing Novavax’s proprietary Matrix-M adjuvant technology, as well as future royalties.
- Beyond the vaccine market, Novavax is also advancing in investing in non-infectious health sectors, as evidenced by their experimental bird flu vaccine, which is expected to receive BARDA support.
- As part of its business strategy, Novavax is leveraging science and medical-conditions research not only in the vaccine industry but also healthcare and wellness, to ensure sustainable growth and continuous innovation.
